Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo

Characteristic

Placebo

(n = 487)

TER

(n = 500)

Women, n (%)

401 (82)

412 (82)

Age,* y

61 (14)

60 (14)

   Range

22–93

20–89

Race, n (%)

  

   White

460 (95)

477 (95)

   Black

19 (4)

17 (3)

   Other

8 (2)

6 (1)

UUI episodes per wk*

23.5 (20.7)

22.3 (22.4)

Micturitions per 24 h*

11.3 (3.8)

10.9 (4.2)

Volume voided per micturition,* mL

135.3 (41.9)

140.1 (42.7)

  1. TER = tolterodine extended release; UUI = urgency urinary incontinence.
  2. *Data are mean (SD).